Gastrointestinal stromal tumor
MONDO:0011719Gastrointestinal stromal tumor (GIST) is the most common mesenchymal neoplasm of the gastrointestinal (GI) tract, typically presenting in adults over the age of 40 (mean age 63), and only rarely in children, in various regions of the GI tract, most commonly the stomach or small intestine but also less commonly in the esophagus, appendix, rectum and colon. GISTs can be asymptomatic or present with various non-specific signs, depending on the location and size of tumor, such as loss of appetite, anemia, weight loss, fatigue, abdominal discomfort or fullness, nausea, vomiting, as well as an abdominal mass, blood in stool, and intestinal obstruction. GISTs can also be seen in familial syndromes such as Carney triad and neurofibromatosis type 1.
Also known as: GIST, Gastrointestinal Stromal Tumors, gastrointestinal stromal neoplasm, gastrointestinal stromal sarcoma, gastrointestinal stromal tumor, gastrointestinal stromal tumor (gist), gastrointestinal stromal tumor, familial, isolated cases, gastrointestinal stromal tumor, isolated cases
1541 clinical trials for this condition and its sub-types, 93 tagged with Gastrointestinal stromal tumor itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Could a daily pill tame rare cancers in teens? new trial investigates
Disease control Not yet recruitingThis phase 2 trial tests the safety of belzutifan, a daily oral tablet, in adolescents with rare solid tumors that cannot be surgically removed or have spread. The study includes three tumor types: pheochromocytoma/paraganglioma (PPGL), wild-type gastrointestinal stromal tumors (…
Phase 2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Can a coordinated care team reduce severe side effects in older cancer patients?
Disease control Not yet recruitingThis trial tests whether a coordinated care pathway, involving oncologists, geriatricians, pharmacists, and pharmacologists, can reduce severe side effects in adults over 70 with certain cancers who are starting oral therapy. Participants receive extra monitoring, including blood…
Phase 4 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Supercharging the Body's own defenses to fight Hard-to-Treat GIST
Disease control Not yet recruitingThis trial tests whether a patient's own immune cells, called tumor-infiltrating lymphocytes (TILs), can be grown in a lab and then given back to fight advanced gastrointestinal stromal tumors (GIST). The study includes people whose GIST has spread, come back, or cannot be remove…
Phase 2 • Sponsor: Joal Beane • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Engineered t cells take on Hard-to-Treat cancers in new trial
Disease control Not yet recruitingThis early-stage study tests a new treatment for people with advanced ovarian cancer or other solid tumors that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells that are genetically modified to better recognize and attack cancer…
Phase 1/2 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New scope technique aims to remove stomach tumors without major surgery
Disease control Not yet recruitingThis study will test a type of endoscopic surgery to remove certain stomach tumors that grow outward from the stomach wall. The goal is to see if this less invasive approach can completely remove the tumors and prevent them from coming back. The study will involve 20 participants…
Sponsor: Zhongda Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Sound wave 'Touch Test' could spot hidden tumors without surgery
Diagnosis Not yet recruitingThis study will test whether a special ultrasound technique called elastography can help doctors tell the difference between harmless and cancerous growths in the chest and digestive tract. About 35 adults will get an endoscopic ultrasound with elastography, and the results will …
Sponsor: Assiut University • Aim: Diagnosis
Last updated Jun 27, 2026 09:05 UTC
-
Metabolic MRI may reveal tumor response to GIST drug in weeks, not months
Knowledge-focused Not yet recruitingThis study tests whether a specialized MRI technique, called hyperpolarized 13C-MRI, can detect early metabolic changes in gastrointestinal stromal tumors (GIST) during treatment with imatinib. Standard scans like CT and MRI only measure tumor size, which can take months to chang…
Sponsor: Chang Gung Memorial Hospital • Aim: Knowledge-focused
Last updated Jul 26, 2026 00:00 UTC
-
Scientists launch massive GIST registry to unlock secrets of rare cancer
Knowledge-focused Not yet recruitingThis registry study will collect medical information and biological samples from 1,000 people with gastrointestinal stromal tumors (GIST), a rare type of digestive tract cancer. The goal is to better understand how GIST behaves, especially in rare forms, and to identify factors t…
Sponsor: Universität Duisburg-Essen • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC